New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
13:18 EDTSIEGY, ALSMY, GEEarnings Preview: General Electric shares little changed since Q1 report
General Electric (GE) is expected to report second quarter earnings on Friday, July 18 before the market open with a conference call scheduled for 8:30 am ET. General Electric is a globally diversified technology and financial services company serving customers in more than 100 countries. EXPECTATIONS: Analysts are looking for earnings per share of 39c on revenue of $36.3B, according to First Call. The consensus range for EPS is 38c-40c on revenue of $35.99B-$36.72B. LAST QUARTER: General Electric reported first quarter adjusted EPS of 33c against estimates for 32c on revenue of $34.18B against estimates for $34.36B. CEO Jeff Immelt said, Were off to a good start to the year, and our 2014 framework remains unchanged. The environment is consistent with our expectations, with a positive bias. During GEs Q1 earnings call, management said the U.S. market gets "a little better every day," and Europe is improving. They said there was some improvement in demand for credit in Q1. They noted the company was on track to reduce share count in 2014, and on track to achieve its margin goal in 2016. The company expected to make gains from divestitures in its industrial portfolio. In June, GE finalized a deal to purchase the Power and Grid businesses of Alstom (ALSMY), after fending off rivals Siemens (SIEGY) and Mitsubishi Heavy Industries. STREET RESEARCH: Street research has been light in the weeks leading up to GE's Q2 earnings report. On May 12, Barclays upgraded the U.S. Multi-Industry sector to Positive from Neutral. The firm's data indicated that Fed policy had extended the cycle, driving up capital spending and corporate confidence. PRICE ACTION: GE shares traded marginally higher following its Q1 report, but currently sit at approximately the same level as they did three months ago. Over the past twelve months, the stock has gained about 13%. In early afternoon trading ahead of tomorrow's Q2 report, GE shares are down almost 1% to $26.76.
News For GE;ALSMY;SIEGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 16, 2014
15:57 EDTGEGE CEO says company planning for 'sluggish' oil & gas performance in FY15
Subscribe for More Information
15:44 EDTGEGeneral Electric sees FY15 EPS $1.70-$1.80, consensus $1.79
Subscribe for More Information
15:18 EDTGEGE CEO says still considering ways to shrink GE Capital in investor-friendly way
Subscribe for More Information
15:14 EDTGEGeneral Electric sees Alstom deal adding about 1c to FY15 EPS
Subscribe for More Information
15:07 EDTGEGeneral Electric sees FY15 Industrial EPS $1.10-$1.20
Subscribe for More Information
15:02 EDTGEGeneral Electric sees returning $10B-$30B to investors in FY15
Subscribe for More Information
14:57 EDTGEGeneral Electric says Alstom synergy opportunities better than expected
Subscribe for More Information
14:54 EDTGEGE repeats view for FY14 revenue flat to up 5%, consensus $148.92B
Subscribe for More Information
10:59 EDTALSMYAlstom could pay nearly $700M in bribery settlement, WSJ reports
Subscribe for More Information
09:22 EDTGEGeneral Electric must answer on oil and gas focus after price slide, WSJ says
Subscribe for More Information
08:03 EDTGEGeneral Electric to acquire Oceaneering's Electric Actuator product line
Subscribe for More Information
05:56 EDTGEBoeing selects GE Aviation for ELMS on 777X
Subscribe for More Information
December 15, 2014
12:01 EDTGEBioTime unit, GE Healthcare sign set of license agreements, terms not disclosed
BioTime (BTX) announced that its subsidiary ES Cell International Pte. Ltd. and GE Healthcare (GE) have signed a set of license agreements through which GEHC received rights to ESIs stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening. In addition, the agreements give GEHC the right to grant sub-licenses to the ESI patent portfolio and, in certain circumstances, ESI may further sublicense its rights for the purpose of marketing stem cell-derived products. Financial terms were not disclosed.
11:17 EDTGEGE Aviation selected by Boeing for 777x common core avionics systems
Subscribe for More Information
08:15 EDTGEGeneral Electric to host investor meeting
Subscribe for More Information
08:08 EDTGEGeneral Electric enters into IP licensing agreement with WordLogic
Subscribe for More Information
December 12, 2014
11:57 EDTGEGeneral Electric increases dividend 5% to 23c from 22c
Subscribe for More Information
11:57 EDTGEGeneral Electric increases dividend 5% to 23c from 22c
Subscribe for More Information
December 10, 2014
08:04 EDTGEGE Energy Financial Services, Pacifico to build second joint solar project
Subscribe for More Information
December 9, 2014
06:52 EDTSIEGYSiemens CEO says won't spend aggressively on M&A, Reuters reports
Siemens CEO Joe Kaeser stated that the company will not spend its money too aggressively in M&A and instead focus on organic growth, fix underperforming units, and looks to increase R&D spending, reports Reuters, citing Kaeser. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use